Breast carcinomas occurring in young women (< 35 years) are different

British Journal of Cancer

Volumn 74, Issue 11, 1996, Pages 1796-1800

  Walker, R A ^a   Lees, E ^a   Webb, M'B ^a   Dearing, S J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Breast cancer; p53 abnormalities; Young age

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HUMAN; HUMAN TISSUE; LUNG CARCINOMA; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL;

EID: 0029844098     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.632     Document Type: Article

References (35)

1. ADAMI HO, MALKER B, HOLMBERG L, PERSONN I AND STONE B. (1986). The relation between survival and age at diagnosis in breast cancer. New Eng. J. Med., 315, 559-563.
2. ALBAIN KS, ALLRED DC AND CLARK GM. (1994). Breast cancer outcome and predictors of outcome: are there age differentials? Monogr. Natl Cancer Trust, 16, 35-42.
3. ALLRED DC, CLARK GM, MOLINA R, TANDON AK, SCHNITT SJ, GILCHRIST KW, OSBORNE CK, TORMEY DC AND MCGUIRE WL. (1992). Over expression of HER-2/neu and its relationship with other prognostic factors change during the progression of in-situ to invasive breast cancer. Hum. Pathol., 23, 974-979.
4. ASSOCIATION OF DIRECTORS OF ANATOMIC AND SURGICAL PATHOLOGY. (1996). Recommendations for the reporting of breast carcinoma. Human Pathol., 27, 220-224.
5. BARNES DM, DUBLIN EA, FISHER CJ, LEVISON DA AND MILLIS RR. (1993). Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indication of prognosis? Hum. Pathol., 24, 469-476.
6. BONNIER P, ROMAIN S, CHARPIN C, LEJEUNE C, TUBIANA N, MARTIN P-M AND PIANA L. (1995). Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int. J. Cancer, 62, 138-144.
7. BRUNN RASMUSSEN B, ROSE C, THORPE SM, HOU-JENSEN K, DAEHNFELDT JL AND PALSHOF T. (1981). Histopathological characteristics and oestrogen receptor content in primary breast carcinoma. Virchows Arch. Pathol. Anal., 390, 347-351.
8. CALEFFI M, TEAGUE MW, JENSEN RA, VNENCAK-JONES CL, DUPONT WD AND PARL FF. (1994). p53 gene mutations and steroid receptor status in breast cancer. Cancer, 73, 2147-2156.
9. CATTORETTI G, BECKER MHG, KEY G, DUCHROW M, SCHLUTER C, GALLE J AND GERDES J. (1992). Monoclonal antibodies against recombinant parts of the Ki-67 antigen (M1B-1 and M1B-3) detect proliferating cells in microwave processed formalin-fixed paraffin sections. J. Pathol., 168, 357-363.
10. CHUNG M, CHANG HR, BLAND KI AND WANEBO HJ. (1996). Younger women with breast carcinoma have a poorer prognosis than older women. Cancer, 77, 97-103.
11. EL-DEIRY WS, HARPER JW, O'CONNER PM, VELCULESCO VE, CANMAN CE, JACKMAN J, PIETENPOL JA, BURREL M, HILL DE, WANG Y, WIMAN KG, MERCER WE, KASTAN MB, KOHN KW, ELLEDGE SJ, KINZIVER KW AND VOGELSTEIN B. (1994). WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res.. 54, 1169-1174.
12. ELSTON CW AND ELLIS IO. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology, 19, 403-410.
13. EYFJORD JE, THORLACIUS S, STEINARSDOTTIR M, VALGARDS-DOTTIR R, OGMUNDSDOTTIR HM AND ANAMTHAWAT-JONSSON K. (1995). p53 abnormalities and genomic instability in primary human breast cancers. Cancer Res., 55, 646-651.
14. FOEKENS JA, PORTENGEN H, VAN PUTTEN WLJ, PETERS HA, KRITJNEN HLJM, ALEXIEVA-FIGUSCH J AND KLIJN JGM. (1989). Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumour cytosols. Cancer Res., 49, 5823-5828.
15. GULLICK WJ, LOVE SB, WRIGHT C, BARNES DM, GUSTERSON B, HARRIS AL AND ALTMAN DG. (1991). C-erbB-2 protein over expression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br. J. Cancer, 63, 434-438.
16. HOST H AND LUND E. (1986). Age as a prognostic factor in breast cancer. Cancer, 57, 2217-2221.
17. JACQUEMIER J, MOLES JP, PENAULT-LLORCA F, ADELAIDE J, TORRENTE M, VIENS P, BIRNBAUM B AND THEILLET C. (1994). p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br. J. Cancer, 69, 846-852.
18. KUERBITZ SJ, PLUNKETT BS, WALSH WV AND KASTAN MB. (1992). Wild-type 53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl Acad. Sci. USA, 89, 7491-7495.
19. MARCUS JN, WATSON P, PAGE DL AND LYNCH HT. (1994). Pathology and heredity of breast cancer in younger women. Monogr. Natl Cancer Inst., 16, 23-34.
20. MAZARS R, SPINARD IL, BENCHEIKH M, SIMONY-LAFONTAINE J, JEANTEUR P AND THEILLET C. (1992). p53 mutations occur in aggressive breast cancer. Cancer Res., 52, 3918-3923.
21. NOYES RD, SPANOS WJ AND MONTAGUE ED. (1982). Breast cancer in women aged 30 and under. Cancer, 49, 1302-1307.
22. PILLERS EMK. (1992). Histological grade of breast cancer in younger women. Lancet, 339, 1483.
23. RAILO M, NORDLING S, VON BOGUSLAWKSKY K, LEIVONEN M, KYLLONEN L AND VONSMITTEN K. (1993). Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br. J. Cancer, 68, 579-583.
24. RAJAKARIAR R AND WALKER RA. (1995). Pathological and biological features of mammographically detected invasive breast carcinomas. Br. J. Cancer. 71, 150-154.
25. REINER A, NEUMEISTER B, SPONA J, REINER G, SCHEMPER M AND JAKESZ R. (1990). Immunocytochemical localisation of estrogen progesterone receptor and prognosis in human primary breast cancer. Cancer Res., 32, 7057-7061.
26. RIBEIRO CG AND SWINDELL R. (1981). The prognosis of breast carcinoma in women aged less than 40 years. Clin. Radiol., 32, 231-236.
27. DE LA ROCHEFORDIERE A, ASSELAIN B, CAMPANA F, SCHOLL SM, FENTON J, VILCOQ JR, DURAND J-C, POUILLART P, MAGIDELENAT H AND FOURQUET A. (1993). Age as a prognostic factor in premenopausal breast carcinoma. Lancet, 341, 1039-1043.
28. ROYAL COLLEGE OF PATHOLOGISTS WORKING GROUP. (1990). NHS Breast Screening Programme: Pathology Reporting in Breast Cancer Screening. Royal College of Pathologists: London.
29. SANT M, GATTA G, MICHELI A, VERDECCHIA A, CAPOCACCIA R, CROSIGNANY P AND BERRINO F. (1991). Survival and age at diagnosis of breast cancer in a population based cancer registry. Eur. J. Cancer, 27, 981-984.
30. THOR AD, MOORE II DH, EDGERTON SM, KAWASAKI E, REIHSAUS E, LYNCH HT, MARCUS JN, SCHWARTZ L, CHEN L-C, MAYALL BH AND SMITH HS. (1992). Accumulation of p53 tumour suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl Cancer Inst., 84, 845-855.
31. WALKER RA AND CAMPLEJOHN RS. (1988). Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. Br. J. Cancer, 57, 281-283.
32. WALKER RA, GULLICK WJ AND VARLEY JM. (1989). An evaluation of immunoreactivity for c-erbB-2 protein as a marker to short-term prognosis in breast cancer. Br. J. Cancer, 60, 426-429.
33. WALLGREN A, SILFVERSWARD C AND HULTBORN A. (1977). Carcinoma of the breast in women under 30 years of age. Cancer, 40, 916-923.
34. WYNFORD-THOMAS D. (1992). p53 in tumour pathology: can we trust immunocytochemistry? J. Pathol., 166, 329-330.
35. YIN Y, TAINSKY MA, BISCHOFF FZ, STRONG LC AND WAHL GM. (1992). Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70, 937-948.